biotech
Colchicine May Prevent Liver Cancer in Viral Hepatitis Patients
Filed in archive Drugs, Vaccines and Therapeutics by ruth on September 11, 2006
colchicine.JPG
According to a new study published in the Cancer journal, colchicine, an anti-inflammatory drug commonly used to treat gout, may be able to prevent liver cancer (hepatocellular carcinoma, HCC) in patients with hepatitis virus-related end-stage liver disease. Out of 186 patients with Cirrhosis of the liver due to viral disease, 116 were treated with colchicine.

They found that only about one in ten (9 percent) of patients treated with colchicine developed HCC compared to more than one in four (29 percent) of untreated cirrhotic patients. In addition, if subjects developed HCC, patients who were treated with colchicine developed HCC later than those not treated with the drug. Colchicine chemoprevention delayed the diagnosis of HCC after cirrhosis onset by an average 72 months (222 months compared to 150 months). Furthermore, colchicine-treated patients survived longer than untreated patients.


Source: John Wiley & Sons, Inc. Newsroom

Permalink: Colchicine May Prevent Liver Cancer in Viral Hepatitis Patients
Tags: cancer  liver  biotech  patients  colchicine  liver+cancer  prevent+liver  colchicine+prevent 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/35980
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Colchicine May Prevent Liver Cancer in Viral Hepatitis Patients:

  • Currently 3.50/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 3.50 out of 2 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!